Reni Benjamin
Stock Analyst at JMP Securities
(1.27)
# 3,619
Out of 4,981 analysts
173
Total ratings
36.17%
Success rate
-17.52%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Reiterates: Market Perform | n/a | $1.15 | - | 8 | Aug 4, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $27.16 | - | 10 | May 15, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $26 → $22 | $6.86 | +220.70% | 14 | May 2, 2025 | |
| CUE Cue Biopharma | Reiterates: Market Outperform | $2 | $0.74 | +170.31% | 5 | Apr 2, 2025 | |
| BCAB BioAtla | Maintains: Market Outperform | $5 → $1 | $0.69 | +43.91% | 9 | Mar 31, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $83.14 | - | 28 | Mar 11, 2025 | |
| ACET Adicet Bio | Reiterates: Market Perform | n/a | $0.80 | - | 5 | Mar 7, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $12 → $4 | $1.43 | +179.72% | 5 | Jan 14, 2025 | |
| CGEN Compugen | Maintains: Market Outperform | $8 → $4 | $1.38 | +189.86% | 1 | Aug 8, 2022 | |
| ADVM Adverum Biotechnologies | Upgrades: Market Perform | n/a | $3.07 | - | 4 | Nov 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.15 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $6.91 | - | 3 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $16 | $0.07 | +23,924.02% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $15.30 | -34.64% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $3.23 | +54.80% | 6 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $8.21 | +241.05% | 11 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $25.78 | - | 2 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $40 | $18.94 | +111.19% | 4 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $1.54 | - | 7 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.27 | - | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $1.11 | +260.36% | 5 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.89 | - | 10 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $9.10 | -12.09% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $45.53 | +31.78% | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $8.39 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $222.75 | +41.41% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $98.85 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $247.81 | +6.94% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $4.21 | +303.80% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.31 | - | 3 | Nov 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $9.09 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $1.56 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $31.75 | -62.20% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $18.06 | - | 1 | Nov 15, 2017 |
Allogene Therapeutics
Aug 4, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $1.15
Upside: -
Inhibrx Biosciences
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $27.16
Upside: -
Bicycle Therapeutics
May 2, 2025
Maintains: Market Outperform
Price Target: $26 → $22
Current: $6.86
Upside: +220.70%
Cue Biopharma
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $2
Current: $0.74
Upside: +170.31%
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $5 → $1
Current: $0.69
Upside: +43.91%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $83.14
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.80
Upside: -
Werewolf Therapeutics
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $1.43
Upside: +179.72%
Compugen
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $1.38
Upside: +189.86%
Adverum Biotechnologies
Nov 12, 2020
Upgrades: Market Perform
Price Target: n/a
Current: $3.07
Upside: -
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.15
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $6.91
Upside: -
Oct 22, 2018
Maintains: Outperform
Price Target: $20 → $16
Current: $0.07
Upside: +23,924.02%
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $15.30
Upside: -34.64%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $3.23
Upside: +54.80%
Jun 4, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $8.21
Upside: +241.05%
Jun 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $25.78
Upside: -
Jun 2, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $18.94
Upside: +111.19%
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $1.54
Upside: -
May 9, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $2.27
Upside: -
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $1.11
Upside: +260.36%
Mar 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.89
Upside: -
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $9.10
Upside: -12.09%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $45.53
Upside: +31.78%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $8.39
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $222.75
Upside: +41.41%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $98.85
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $247.81
Upside: +6.94%
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $4.21
Upside: +303.80%
Nov 15, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $0.31
Upside: -
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $9.09
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $1.56
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $31.75
Upside: -62.20%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $18.06
Upside: -